

Aberrant calcium signaling in astrocytes inhibits neuronal excitability in a human Down syndrome stem cell model

Grace O. Mizuno ^{1†}, Yinxue Wang^{3†}, Guilai Shi^{1†}, Yizhi Wang³, Junqing Sun², Stelios Papadopoulos¹, Gerard J. Broussard¹, Elizabeth K. Unger¹, Wenbin Deng⁷, Jason Weick⁵, Anita Bhattacharyya⁴, Chao-Yin Chen², Guoqiang Yu³, Loren L. Looger⁶, Lin Tian^{1*}

¹University of California, Davis, Department of Biochemistry and Molecular Medicine, Department of Psychiatry and Behavioral Sciences, Davis, CA

²University of California, Davis, Department of Pharmacology, Davis, CA

³Virginia Polytechnic Institute and State University, Bradley Department of Electrical and Computer Engineering, Blacksburg, VA

⁴University of Wisconsin, Madison, Waisman Center, Madison, WI

⁵University of New Mexico, Department of Neuroscience, Albuquerque, NM

⁶Howard Hughes Medical Institute, Janelia Research Campus, Ashburn, VA

⁷University of California, Davis, Department of Biochemistry and Molecular Medicine, Shriners' Hospital, Davis, CA

† These authors contributed equally

* Correspondence: lintian@ucdavis.edu

Tel # (530) 752-8667

1 **Abstract**

2 Down syndrome (DS) is a devastating genetic disorder causing severe cognitive impairment.
3 The staggering array of effects associated with an extra copy of human chromosome 21
4 (HSA21) complicates mechanistic understanding of DS pathophysiology. We developed an in
5 vitro system to examine the interplay of neurons and astrocytes in a fully recapitulated HSA21
6 trisomy model differentiated from DS patient-derived induced pluripotent stem cells (iPSCs). By
7 combining calcium imaging with genetic approaches, we utilized this system to investigate the
8 functional defects of DS astroglia and their effects on neuronal excitability. We found that,
9 compared with control isogenic astroglia, DS astroglia exhibited more-frequent spontaneous
10 calcium fluctuations, which reduced the excitability of co-cultured neurons. DS astrocytes
11 exerted this effect on both DS and healthy neurons. Neuronal activity could be rescued by
12 abolishing astrocytic spontaneous calcium activity either chemically by blocking adenosine-
13 mediated astrocyte–neuron signaling or genetically by knockdown of inositol triphosphate (IP₃)
14 receptors or S100 β , a calcium binding protein coded on HSA21. Our results suggest a novel
15 mechanism by which DS alters the function of astrocytes, which subsequently disturbs neuronal
16 excitability. Furthermore, our study establishes an all-optical neurophysiological platform for
17 studying human neuron-astrocyte interactions associated with neurological disorders.
18

19 **Significant statement**

20 Down syndrome (DS) is the most common genetic disorder caused by trisomy of chromosome
21 21 (HSA21). Problems with cognitive impairment, have not been properly addressed due to the
22 inability to fully recapitulate HSA21, which is further confounded by the snapshot views of
23 morphological changes of brain cells in isolation obtained from current studies. The brain
24 develops neural networks consisting of neurons and glial cells that work together. To
25 understand how DS affects the neural networks, we used DS patient-derived stem cells and
26 calcium imaging to investigate functional defects of DS astrocytes and their effects on neuronal
27 excitability. Our study has significant implication in understanding functional defects during brain
28 development underlying DS.

29

30 **Introduction**

31 Down syndrome (DS) is a neurodevelopmental disorder occurring in 1 in 750 live births
32 worldwide. DS is caused by trisomy of chromosome 21 (Ts21)¹, leading to triplication of up to
33 400 genes, resulting in an array of phenotypes, including profoundly impaired cognitive function.
34 The brains of DS patients demonstrate consistent pathophysiological changes, such as reduced
35 volume, altered neuronal densities and structure, and disturbed balance of all cell types.
36 Confronted with this genetic complexity, it is difficult to determine precise molecular and cellular
37 mechanisms of disease establishment and maintenance. Consequently, there are no
38 therapeutic approaches to mitigate the effects of DS.

39
40 To date, DS pathophysiology has been primarily studied in rodent models, (e.g. Ts65Dn, Ts1cje
41 and Ts1Rhr)². Though useful information has been revealed, rodent models do not faithfully
42 reproduce DS pathophysiology, due in part to incomplete synteny between HSA21 and the
43 homologous mouse regions. Furthermore, rodent modeling of complex neurodevelopmental
44 disorders such as DS is limited by the fact that the human brain is far more complicated than the
45 rodent brain in terms of structure of the neural circuitry, plasticity, and cognitive capacity.

46
47 Advances in induced pluripotent stem cell (iPSC) technology have enabled the modeling of
48 complex diseases such as DS in the context of human cell biology^{3,4}. These models are highly
49 desirable for understanding disease neuropathophysiology and for developing therapeutics. By
50 culturing iPSCs from DS individuals it is possible to achieve full expression of the human HSA21
51 region. In addition, the use of isogenic control lines eliminates inter-individual variability,
52 restricting genotype differences solely to HSA21 dosage.

53
54 Recently, two Ts21-iPSC derived DS models have been reported. Weick et al. established
55 Ts21-iPSC lines from two sets of human fibroblasts and differentiated them into neurons. They

56 found that Ts21-neurons displayed reduced synaptic activity compared to control neurons, while
57 maintaining the ratio of differentiated excitatory and inhibitory neurons. Chen et al., on the other
58 hand, engineered Ts21 iPSCs from a different human fibroblast line and reported that
59 conditioned medium from Ts21-iPSC derived astroglia had a toxic effect on neuronal maturation
60 and survival. Although these two elegant studies provide complementary perspectives on the
61 defects of human neurons or astroglia associated with DS, they studied neurons and astrocytes
62 in isolation. Growing evidence suggests that astrocytes substantially contribute to neurological
63 and psychiatric disorders by affecting neuronal function⁵⁻⁹. Indeed, astrocytes have been
64 implicated in multiple rodent studies as playing an important role in DS^{10,11}. A number of genes
65 involved in DS, including TSP-1 and APP have been shown to be expressed in astrocytes and
66 have been implicated in Alzheimer's disease^{12,13}. A complete mechanistic understanding of DS
67 pathophysiology requires studying the communication between neurons and astrocytes at the
68 network level.

69
70 Unlike neurons, whose excitable membranes allow action potentials to be transmitted cell-wide
71 within milliseconds, astrocyte-wide signaling occurs *via* intracellular calcium (Ca^{2+}) transients
72 lasting for seconds¹⁴. These intracellular Ca^{2+} transients can be triggered by neuronal activity¹⁵
73 and are thought to induce release of gliotransmitters such as glutamate, GABA, ATP and D-
74 serine¹⁶⁻¹⁹, which in turn modulate neural activity. Although gliotransmitter identity and release
75 mechanisms are controversial²⁰⁻²², intracellular Ca^{2+} dynamics are generally acknowledged to
76 encode astrocyte activity. More importantly, altered astrocyte calcium dynamics were reported
77 in cultured cells from the rodent DS models^{13,23}.

78
79 Based on these previous studies, we hypothesized that DS could affect neuronal excitability
80 through altered astrocytic Ca^{2+} dynamics, leading to alterations in astrocyte-neuron signaling
81 pathways. Therefore, we differentiated the Ts21-iPSC lines reported in Weick et al. to

82 astrocytes and neurons to establish a novel Ts21-iPSC-derived neuron-astrocyte co-culturing
83 system to uncover functional deficits of neural networks. We focused on astrocytic Ca^{2+}
84 dynamics and the specific interactions between astrocytes and neurons. We show that aberrant
85 Ca^{2+} fluctuations in human DS astrocytes reduce the excitability of co-cultured human neurons
86 and alter their synaptic properties. These effects are mediated by overexpression of the HSA21
87 protein S100 β . Our study explores the contribution of astrocytes to abnormal neural circuit
88 development, beyond the traditional view of trophic, supporting roles, and suggests causal roles
89 of HSA21 gene overload in DS etiopathogenesis.

90 **Results**

91 **Generation and differentiation of astroglia from human Ts21 iPSCs**

92 Using established protocols²⁴, we differentiated astroglia from previously reported iPSC lines by
93 Weick et al., DS1 and DS4, which are trisomic for chromosome 21, and DS2U, a control
94 isogenic line (**Supplementary Fig. 1a-b**)⁴. After 120 days, all three iPSC lines robustly
95 expressed astrocyte precursor marker CD44, mature astrocyte markers glia fibrillary acidic
96 protein (GFAP) and aquaporin 4 (AQP4), as determined by immunofluorescence and confirmed
97 by quantitative reverse transcription PCR (qPCR) (**Supplementary Fig. 1d-f, Supplementary**
98 **Table 1**). Karyotype analysis prior to and after experiments confirmed trisomy of DS1- and
99 DS4-derived astroglia (DS1A and DS4A) and disomy of DS2U-induced astroglia (DS2UA)
100 (**Supplementary Fig. 1b**). Using qPCR, we further observed global expression of a panel of
101 astrocyte specific markers such as excitatory amino acid transporter 1 (*EAAT1*), aldolase C
102 (*ALDOC*), connexin-43 (*CX43*), *SOX9*, and nuclear factor I A (*NFIA*) in all three lines
103 (**Supplementary Fig. 1c**)⁹, indicating successful astroglia differentiation of the iPSCs.
104 Consistent with previous reports, DS astroglia showed increased expression levels of HSA21
105 genes compared to control astroglia, including *S100 β* ²⁵, amyloid beta precursor protein (*APP*)²³
106 and transcription factor *ETS2*²⁶, as well as higher levels of non-HSA21 genes associated with
107 oxidative stress, such as catalase (*CAT*)²⁷ and quinone oxidoreductase
108 (*CRYZ*)⁴(**Supplementary Fig. 1c**). Morphologically, DS astroglia occupied larger territories than
109 DS2UA; the total arborization size of DS astrocytes was significantly greater than that of control
110 isogenic astroglia (**Supplementary Fig. 1g**).

111


112 **DS astroglia inhibit the excitability of co-cultured neurons**

113 We next studied the potential influence of DS astroglia on co-cultured neurons. Using
114 established protocols^{28,29}, three lines of cortical TUJ1⁺ (neural-specific β -III tubulin) neurons

115 were differentiated from the DS1 and DS2U iPSC lines and a control H9 human embryonic stem
116 cell (hESC) line (**Supplementary Fig. 2a–b**). Differentiated neurons were infected with
117 lentivirus encoding GCaMP6m driven by the neuron specific promoter *synapsin-1*
118 (**Supplementary Fig. 2c**). To establish a baseline of neuronal excitability, we monitored
119 fluorescence changes in neurons in response to a series of electrically evoked field potentials
120 (FPs) in the absence of astrocytes. The magnitude of evoked Ca^{2+} transients in neurons
121 increased with the number of applied FPs (**Fig. 1a**). Evoked signals were abolished by addition
122 of 1 μM tetrodotoxin (TTX; a voltage-gated sodium channel blocker) (**Fig. 1a**), suggesting that
123 Ca^{2+} signals in neurons were triggered by action potentials. The expression of multiple voltage-
124 gated sodium-channel isoforms in differentiated neurons was confirmed by qPCR assay
125 (**Supplementary Fig. 2d**).

126
127 After confirming the basis of neuronal excitability, we recorded neuronal activity when co-
128 cultured with DS1-, DS4-, or DS2U-derived astroglia, as well as human primary astrocytes (HA).
129 H9 hESC-derived neurons co-cultured with DS astroglia (DS1A or DS4A) showed significantly
130 decreased FP-evoked Ca^{2+} amplitudes relative to neurons cultured alone (normalized $\Delta\text{F}/\text{F}$;
131 DS1A: 0.63 ± 0.06 , $P=0.0042$; DS4A: 0.57 ± 0.05 , $P<0.001$), whereas neurons co-cultured with
132 control isogenic astrocytes (DSU2A) or human primary astrocytes were not significantly affected
133 (DS2UA: 1.00 ± 0.04 , $P=0.93$; HA: 0.88 ± 0.04 , $P=0.059$; **Fig. 1b**).

134



135

136 **Figure 1. DS astroglia inhibit neuronal excitability during co-culture.** (a) The fluorescence changes ($\Delta F/F$) of H9 hESC-derived
 137 neurons in response to a variety of FP stimuli; $\Delta F/F$ at 10 FPs, 40 FPs, and 40 FPs in the presence of 1 μM TTX were normalized to
 138 $\Delta F/F$ at 80 FPs. (b–d) The responses of H9 hESC- (b), isogenic DS2U- (c), and DS1-iPSC- (d) derived neurons to FP stimuli (40
 139 FPs at 30Hz) when co-cultured with or without astroglia. $\Delta F/F$ induced by FP stimuli in the presence of astrocytes was normalized to
 140 that of neurons alone (red dotted lines). Representative traces showing Ca^{2+} transients triggered by FPs in neurons are shown (right
 141 panel). (e) Example recordings of mEPSCs from 1 neuron from each group. (f) Cumulative probability of the mEPSC amplitude
 142 shifted rightward in both DS4A and DS1A groups compared with the DS2UA group. (g) No change was seen in the cumulative
 143 probability of the mEPSC inter-event interval. (h) Representative images and quantification of puncta expressing both pre-
 144 synaptic protein synapsin and post-synaptic scaffolding protein PSD95 on oblique dendrites of co-cultured rat hippocampal neurons.
 145 (i) The fluorescence changes of H9 hESC-derived neurons in response to 40 FPs stimuli when co-cultured with DS4A in the
 146 presence of DMSO or a series of drugs are shown and normalized to changes when co-cultured with DS2UA. Several compounds
 147 showing therapeutic effect in DS mouse models had no rescuing effect on neuronal activity when co-cultured with DS4A, except
 148 DPCPX, an A1-receptor antagonist. The fluorescence changes of H9 hESC-derived neurons, in response to 40 FPs stimuli when
 149 co-cultured with DS4A in the presence of DMSO or a series of drugs, are shown and normalized to fluorescence changes when co-
 150 cultured with DS2UA.

151

152 Similar neuronal-activity suppression imposed by DS astroglia was also observed in neurons
153 derived from the two other iPSC lines. DS2U derived neurons co-cultured with DS astroglia
154 (DS1A or DS4A) showed significantly decreased FP-evoked Ca^{2+} amplitudes relative to neurons
155 cultured alone (normalized $\Delta\text{F}/\text{F}$; DS1A: 0.57 ± 0.04 , $P < 0.001$; DS4A: 0.51 ± 0.04 , $P < 0.001$;
156 DS2UA: 0.99 ± 0.03 , $P = 0.89$; HA: 0.93 ± 0.04 , $P = 0.18$; **Fig. 1c**). Likewise, DS1 derived neurons
157 co-cultured with DS astroglia (DS1A or DS4A) showed significantly decreased FP-evoked Ca^{2+}
158 amplitudes relative to neurons cultured alone (normalized $\Delta\text{F}/\text{F}$; DS1A: 0.66 ± 0.07 , $P = 0.0092$;
159 DS4A: 0.43 ± 0.05 , $P < 0.001$; DS2UA: 0.92 ± 0.04 , $P = 0.15$; HA: 0.95 ± 0.03 ; $P = 0.18$; **Fig. 1d**).
160 Decreased neuronal activity in the presence of DS astroglia was observed under a variety of
161 stimulation conditions, but was most prominent during modest stimulation such as 10FPs
162 (**Supplementary Fig. 2e**). Taken together, DS astroglia inhibited neuronal excitability of
163 neurons derived from either trisomy or disomy iPSC lines.

164
165 In addition, all co-cultured astrocytes significantly accelerated decay-to-baseline of evoked
166 neuronal Ca^{2+} transients ($T_{0.5} = 1.62 \pm 0.14$ for neuron-alone; $T_{0.5} = 1.22 \pm 0.08$, 1.25 ± 0.12 ,
167 1.11 ± 0.13 , and 1.18 ± 0.1 for neurons co-cultured with HA, DS2UA, DS1A, and DS4A
168 respectively, $P < 0.01$; **Supplementary Fig. 2f**), presumably because astrocytic glutamate
169 clearance following FP-evoked release occurs at similar rates.

170

171 **DS astroglia promote synaptic connectivity**

172 As DS astroglia suppress neuronal activity, we next sought to determine if DS astroglia
173 influence synaptic function. DS astroglia were co-cultured with dissociated rat hippocampal
174 neurons, and miniature excitatory post-synaptic currents (mEPSCs) were recorded in the
175 presence of TTX, NMDA receptor antagonist D-AP5, and GABA_A antagonist bicuculline, to
176 isolate the fast AMPA receptor-mediated mEPSC component (**Fig. 1e–g, Supplementary Fig.**
177 **2g–h**). Cumulative distribution plots showed that the mean amplitude of mEPSCs was

178 significantly larger in neurons co-cultured with either DS4A and DS1A groups compared with
179 control DS2UA (DS2UA: 14.21 ± 0.42 ; DS1A: 16.35 ± 0.78 , $P=0.032$; DS4A: 16.26 ± 0.73 , $P=0.019$;
180 Fisher's least-significant difference test) (**Fig. 1f**, **Supplementary Fig. 2g**, $P<0.05$). mEPSC
181 frequency was similar in all three groups, with a trend towards higher mEPSC frequencies in the
182 neurons co-cultured with DS4A and DS1A groups ($P=0.204$; DS2UA: 0.56 ± 0.06 ; DS1A:
183 1.29 ± 0.45 ; DS4A: 1.10 ± 0.36) (**Fig. 1g**, **Supplementary Fig. 2h**).

184
185 We next evaluated the effects of human astroglia on synapse formation using quantitative
186 image analysis³⁰. We quantified the density of punctae expressing both the pre-synaptic protein
187 synapsin-I and the post-synaptic scaffolding protein PSD95 on oblique dendrites of rat
188 hippocampal neurons co-cultured with astroglia. We found that synapse density significantly
189 increased by 1.5- and 1.3-fold in neurons co-cultured with DS astrocytes (DS1A, ($P=0.0039$);
190 DS4A, ($P=0.02$), respectively) compared with those co-cultured with isogenic control astrocytes
191 (**Fig. 1h**). Taken together, these results suggest that DS astroglia are capable of modulating
192 neuronal excitability, as well as synaptic activity and density.

193

194 **Pharmacological rescue of suppressed neuronal excitability**

195 We next examined whether pharmacological drugs that block astrocyte-neuron communication
196 could rescue the suppressed neuronal excitability. We examined a panel of small molecule
197 drugs that have been shown to rescue synaptic abnormalities in DS mouse models³¹. These
198 compounds, including purmorphamine (sonic hedgehog agonist), CGP52432 (GABA_BR
199 antagonist), epigallocatechin-3-gallate (EGCG, DYRK1A inhibitor), fluoxetine (serotonin
200 reuptake inhibitor), and memantine (NMDA receptor antagonist) failed to rescue decreased
201 neuronal activity associated with DS astroglia (normalized $\Delta F/F=0.60 \pm 0.04$, 0.68 ± 0.03 ,
202 0.70 ± 0.02 , 0.71 ± 0.03 , and 0.68 ± 0.06 , from purmorphamine to memantine; $P=0.22$, 0.95 , 0.73 ,

203 0.67, 0.93; $n=3$; **Fig. 1i**).

204

205 Next we examined the chemical transmitter ATP, since astrocytic release of ATP has been
206 shown to modulate synaptic function, with intracellular Ca^{2+} transients increasing probability of
207 release^{16,18,19}. To what extent ATP potentiates and/or inhibits neuronal activity is still under
208 debate; however, adenosine, a rapid ATP breakdown product, has been shown to inhibit
209 synaptic activity via G_i -coupled A_1 adenosine receptors³²⁻³⁶. To test whether suppressed
210 neuronal excitability is caused by adenosine-mediated signaling, we treated H9 neurons co-
211 cultured with DS astroglia (DS4A) with an adenosine receptor antagonist, followed by imaging
212 FP-evoked neuronal activity. In particular, the A_1 receptor antagonist DPCPX fully rescued
213 suppressed neuronal activity, especially at lower concentrations (100 nM: normalized
214 $\Delta F/F=1.20\pm 0.09$, $P=0.004$; 1 μM : 0.98 ± 0.08 , $P=0.018$; $n=3$; **Fig. 1i**). This suggests that the
215 suppressed neuronal excitability is influenced by purinergic signaling.

216


217 **DS astroglia exhibit abnormally frequent spontaneous Ca^{2+} fluctuations**

218 Astrocytic Ca^{2+} signaling has been proposed to modulate neural-circuit activity and structure^{37,38};
219 the suppressed excitability of neurons was specific to DS astroglia and could be rescued when
220 astrocyte-neuron communication was blocked by an adenosine receptor antagonist. This
221 evidence led us to further investigate calcium dynamics in astroglia. We focused on optical
222 recordings of calcium dynamics in astroglia using the genetically encoded indicator GCaMP6m³⁹.
223 We used the machine-learning software Functional Astrocyte Phenotyping (FASP)⁴⁰ to facilitate
224 automated detection and analysis of complex Ca^{2+} dynamics in astroglia.

225

226 The differentiated astroglia indeed displayed prominent spontaneous Ca^{2+} transients, which
227 were frequently periodic and especially apparent in DS astroglia (**Fig. 2a, Supplementary**
228 **Movie 1&2**). DS astroglia exhibited significantly more (7–34-fold) Ca^{2+} transients than control

229 isogenic astroglia (averaged number of calcium transients in a 5-min imaging session: DS1A:
230 58 ± 6 , DS4A: 275 ± 34 , DS2UA: 8 ± 2 , mean \pm s.e.m.; $P < 0.0001$, unpaired t-test, $n = 9$ imaging
231 sessions) (**Fig. 2b**). The average amplitude ($\Delta F/F$; DS1A: 1.45 ± 0.2 , DS4A: 0.98 ± 0.15 ; $P < 0.01$)
232 (**Fig. 2c**) and frequency (transients/min; DS1A: 0.41 ± 0.10 , DS4A: 0.88 ± 0.16 ; $P < 0.01$) (**Fig. 2d**)
233 of Ca^{2+} transients were significantly different between DS1A and DS4A, whereas the kinetics
234 were similar ($T_{1/2}$, s; DS1A: 8.59 ± 1.01 , DS4A: 6.98 ± 0.90 ; $P = 0.18$) (**Fig. 2e**). These disparities
235 are potentially due to epigenetic changes between the cell lines.



236

237 **Figure 2. Imaging Ca^{2+} events in human iPSC-derived isogenic and DS astroglia.** (a) Spontaneous Ca^{2+} responses in isogenic
 238 DS2UA and two DS astroglia (DS1A and DS4A). Representative ROIs ($n=20$) in the field of view showing Ca^{2+} fluctuations in
 239 DS2UA, DS1A, and DS4A. All ROIs were detected using FASP and marked with magenta outlines. Scale bars: 100 μm . (b) DS1A
 240 and DS4A displayed a significantly increased number of Ca^{2+} fluctuations in 5 min of imaging sessions, compared with DS2UA (9
 241 independent imaging sessions). Features of Ca^{2+} fluctuations in DS astroglia (c–e): averaged kinetics (c), frequency (d), and

242 propagation speed (e) of DS astroglia. Data were collected from 81 cells of DS1A and 188 cells of DS4A. (f-i) The Ca^{2+} fluctuations
243 in DS4A could be abolished by incubation with IP_3 R antagonist (500 μM 2-APB, 17 ROIs, f & h) or depleting ER Ca^{2+} store (20 μM
244 CPA, 23 ROIs, g & i) $P < 0.01$ (**), unpaired t-test. Error bars represent mean \pm s.e.m.

245
246 Inositol triphosphate (IP_3)-triggered Ca^{2+} release from the endoplasmic reticulum (ER) is
247 considered a primary mechanism responsible for intracellular global Ca^{2+} waves⁴¹. Application
248 of the IP_3 receptor (IP_3 R) antagonist 2-aminoethoxydiphenyl borate (2-APB) abolished
249 spontaneous Ca^{2+} fluctuations (**Fig. 2f–i**), as did depletion of intracellular stores by
250 cyclopiazonic acid (CPA), suggesting that IP_3 -ER Ca^{2+} underlies both spontaneous and evoked
251 events in DS astroglia.

252
253 Wavefront analysis of the spontaneous events revealed 33 clusters of cells (**Supplementary**
254 **Fig. 3a**, left) in one field of view with temporally correlated Ca^{2+} fluctuations (**Supplementary**
255 **Fig. 3a**, right). Cells within a waveform cluster were spatially intermingled, with identical
256 distance distributions between temporally correlated and non-correlated cells (**Supplementary**
257 **Fig. 3b**), suggesting that Ca^{2+} fluctuations do not propagate to adjacent cells. To further
258 examine whether spontaneous fluctuations travel between cells, we performed Ca^{2+} imaging in
259 a mixed culture of GCaMP6m-expressing control isogenic astroglia with unlabeled DS4A, in a
260 variety of ratios. Culturing with DS astroglia did not significantly increase the number of Ca^{2+}
261 transients in control isogenic astroglia, even with a 10-fold excess of DS4A (**Supplementary**
262 **Fig. 3c**), suggesting that spontaneous Ca^{2+} fluctuations were not induced in previously silent
263 control isogenic cells. In addition, application of 10 μM *n*-octanol, a gap junction blocker,
264 showed no effect on Ca^{2+} fluctuations (**Supplementary Fig. 3d**). Taken together, these results
265 indicate that the abnormal spontaneous Ca^{2+} fluctuations observed in DS astroglia are likely the
266 result of cell-autonomous changes.

267

268 Previous studies reported that acutely purified human astrocytes acquire sensitivity to
269 extracellular cues such as neurotransmitter ATP and glutamate⁴². To exclude the possibility that
270 differences in functional maturation of differentiated astroglia contributing to suppressed
271 neuronal excitability, we examined transmitter-evoked Ca²⁺ responses of DS astroglia and
272 compared with isogenic controls. Both DS and control isogenic astroglia responded robustly to
273 ATP (representative traces shown in **Supplementary Fig. 4a-b**) in terms of the number and
274 amplitude of intracellular Ca²⁺ transients. Similarly, both DS astroglia and control isogenic
275 astroglia responded to glutamate at micromolar concentrations (**Supplementary Fig. 4c-d**).
276 Thus, DS and control astroglia respond similarly to neurotransmitters, further suggesting that
277 Ts21 does not influence functionally maturation of differentiated astrocytes.

278


279 **Blocking spontaneous Ca²⁺ fluctuations in DS astroglia rescues suppressed neuronal** 280 **excitability**

281 We next tested whether the suppression of neuronal activity might be caused by the abnormally
282 frequent spontaneous Ca²⁺ fluctuations observed in DS astroglia. Since pharmacological block
283 of IP₃ receptors abrogated spontaneous Ca²⁺ waves (**Fig.2f-i**), we knocked down (KD) the
284 expression of *IP₃R2*, the main *IP₃R* isoform in astrocytes, with short hairpin RNAs (shRNAs) in
285 DS astroglia DS4A. *IP₃R2* KD, corresponding to ~50% knockdown (**Fig. 3b**), significantly
286 reduced the number of active ROIs showing spontaneous Ca²⁺ transients [scrambled shRNA:
287 61.0±3.8; *IP₃R2* shRNA-1: 21.3±2.4 (35%), *IP₃R2* shRNA-2: 14.3±1.8 (24%); *P*<0.001] (**Fig.**
288 **3a,c**), supporting the pharmacological results.

289

290 We next imaged the activity of neurons co-cultured with DS4A astroglia with knocked-down
291 *IP₃R2*. This rescued the reduced amplitude of evoked neuronal Ca²⁺ transients (measured as
292 normalized $\Delta F/F$; *IP₃R2* shRNA-1: 0.91±0.04, shRNA-2: 0.93±0.03) to the level of isogenic
293 control astroglia (1.01±0.04, *P*=0.28). In contrast, DS4A with no shRNA (0.60±0.05, *P*=0.0031)

294 or control-scrambled shRNA (0.62 ± 0.04 , $P=0.0018$) showed significantly decreased neural
 295 activity (**Fig. 3d**). Therefore, elevated intracellular Ca^{2+} fluctuation mediated by IP_3R is
 296 necessary to suppress neuronal excitability.



297
 298 **Figure 3. DS astroglial Ca^{2+} fluctuations are regulated by IP_3R -ER pathway.** (a–c) The Ca^{2+} events in DS4A were significantly
 299 decreased by knocking down the expression of IP_3R . Representative ROIs ($n=20$) showing Ca^{2+} fluctuations in DS4A expressing
 300 scrambled shRNA (ctrl shRNA) and two shRNAs for IP_3R (IP_3R shRNA-1/2) (a). Real-time PCR confirmed the decreased expression
 301 of IP_3R in the presence of IP_3R shRNAs (3 RNA samples, b), corresponding to a decreased number of Ca^{2+} events in 5 min (3
 302 imaging sessions, c). (d) Normalized fluorescence changes of H9 hESC-derived neurons in response to 40 FPs co-cultured with
 303 DS4A or DS4A expressing scrambled or IP_3R shRNAs to those of neurons alone (dotted red line).

304
 305 **Spontaneous Ca^{2+} fluctuations in DS astroglia are not driven by extracellular cues**


306 As elevated spontaneous astroglia Ca^{2+} activity directly contributed to suppressed neuronal
 307 activity, we next sought to determine the factors driving elevated Ca^{2+} activity in DS astroglia.
 308 We first performed single-cell analysis of gene expression related to Ca^{2+} signaling pathways
 309 (mGluRs, purinergic receptors, GPCRs, and Ca^{2+} pumps; **Supplementary Fig. 5a**) in DS
 310 astroglia. We also monitored the expression of a panel of astrocytic markers to account for the
 311 differentiation state of individual cells (**Supplementary Fig. 5a-b**). We then performed
 312 unsupervised clustering analysis of the cells by their gene expression patterns. We found that

313 DS astroglia (e.g. DS4A) clustered into two groups (**Supplementary Fig. 5d**), distinguished by
314 elevated expression of Ca²⁺ handling genes such as *ATP2B1*, *NCX1*, *RYR1/3*, *STIM1*, *NCLX*,
315 *IP3R3*, *ORAI1*, and chromosome 21 gene *S100β* (**Supplementary Table 1**). This suggests that
316 a subset of DS astroglia may display elevated spontaneous Ca²⁺ fluctuations. In DS astroglia,
317 astrocytic markers such as *CD44*, *CX43*, *AQP4*, *NF1A*, and *ALDOC*, were not differentially
318 expressed between the two clusters.

319
320 We next performed a similar analysis of gene expression patterns in control isogenic astroglia
321 (e.g. DS2UA). In contrast, we failed to identify significant clustering (**Supplementary Fig. 5c**) of
322 genes related to the Ca²⁺-handling toolkit.

323
324 Moreover, from the single-cell gene analysis, we found that metabotropic glutamate receptors
325 (*GRM1/2/3/4/5/6/7/8*) and purinergic receptors were elevated in a subset of DS4UA. We next
326 investigated whether spontaneous fluctuations in DS astroglia could be modulated by
327 pharmacological manipulation of these receptors. ATP treatment led to a 2-fold increase in the
328 frequency and a 1.4-fold increase in the amplitude of spontaneous Ca²⁺ fluctuations in ~40% of
329 regions of interest (ROIs) (**Fig. 4a**). However, treatment with P2 isotype-specific ATP receptor
330 antagonists (PPADS for P2X, MRS2179 for P2Y; **Fig. 4b**, **Supplementary Fig. 6b**), non-
331 specific P2 antagonists (suramin; **Fig. 4c**), or an adenosine A₁-receptor antagonist (DPCPX; **Fig.**
332 **4d**) had no significant effect on spontaneous Ca²⁺ fluctuations, suggesting that while ATP can
333 modulate spontaneous Ca²⁺ events in DS astroglia, it is not sufficient to evoke them. CHPG (a
334 selective mGluR5 agonist) showed no significant effects on amplitude, frequency, or kinetics of
335 spontaneous Ca²⁺ fluctuations (**Supplementary Fig. 6a**). Similarly, mGluR5-selective (MPEP),
336 non-selective mGluR (MCPG), and mGluR2/3-selective (LY341495) antagonists, as well as a
337 glutamate transporter inhibitor (TFB-TBOA), also had no effect (**Fig. 4e**, **Supplementary Fig.**
338 **6c–e**). The TRPA1 channel antagonist HC030031 also had no significant effect on spontaneous

339 Ca^{2+} fluctuations (**Fig. 4f**), consistent with the lack of microdomain Ca^{2+} activity observed⁴³. In
340 summary, while both intrinsically and extrinsically driven calcium transients depend on IP_3 -
341 mediated release from ER stores, our results suggest that spontaneous fluctuations are unlikely
342 to be driven, though can be modified, by extracellular cues.
343



344
345 **Figure 4. Spontaneous fluctuations in DS astroglia could not be modulated by pharmacological manipulation.** (a) ATP
346 increased the frequency and amplitude of Ca^{2+} events in previously active cells (20 ROIs were separately selected for either
347 frequency or amplitude, $P < 0.01$). (b–c) Purinergic receptor antagonist (20 μM PPADS, 25 ROIs, b), (20 μM suramin, 18 ROIs, c)
348 failed to modulate the Ca^{2+} fluctuations in DS4A. (d) A1 adenosine receptor antagonist (DPCPX 20 μM, 18 ROIs), (e) mGluR5
349 antagonist (10 μM MPEP, 42 ROIs), and (f) TRPA inhibitor (50 μM HC30031, 20 ROIs) failed to modulate the Ca^{2+} fluctuations in
350 DS4A. Left: representative traces. Right: quantification of amplitude, frequency, and kinetics. $P < 0.01$ (**), unpaired t-test. Error bars
351 represent mean ± s.e.m.

352

353 **S100β regulates spontaneous Ca^{2+} fluctuations in DS astroglia**

354 From gene analysis, we also noticed that S100β, a Ca^{2+} -binding protein located on HSA21 and

355 primarily expressed in astrocytes, was one of the top genes differentially expressed across
356 DS4A cells. Previous studies reported that astrocytes release S100 β , eliciting neurotrophic
357 effects and regulating synaptic plasticity and rhythmic neuronal activity by chelating extracellular
358 calcium^{44,45}. Given the particular interest in the context of Ts21 DS, we thus asked the question
359 whether elevated S100 β might contribute to the spontaneous intracellular Ca²⁺ fluctuations in
360 DS astroglia.

361
362 We first quantified the expression level of S100 β in Ts21-derived astroglia. qPCR analysis
363 showed an averaged 11-fold greater expression of *S100 β* in DS astroglia (DS1A and DS4A)
364 compared with control isogenic DS2UA cells (**Supplementary Fig. 1c**). Expression of S100 β
365 protein was enriched in DS astroglia compared to DS2UA (**Fig. 5a–b**; 9.9- and 10.7-fold
366 increased expression S100 β , for DS1A and DS4A, respectively, compared to DS2UA).


367
368 We next selectively knocked down *S100 β* in DS4A, and performed Ca²⁺ imaging. We co-
369 expressed mCherry as a proxy for the extent of *S100 β* KD and used fluorescence-activated cell
370 sorting (FACS) to select the top 15% of cells with potent *S100 β* KD and use the bottom 15% of
371 cells as a control group with normal *S100 β* levels (**Supplementary Fig. 7a**). The *S100 β* KD
372 population contained ~10-fold lower *S100 β* levels compared to the control group ($P < 0.001$) (**Fig.**
373 **5d**), indicative of effective *S100 β* KD. *S100 β* KD led to a 3.5-fold decrease in spontaneous Ca²⁺
374 transients during a 5-minute window ($P < 0.001$; **Fig. 5c, e**). These data suggest that S100 β
375 modulates spontaneous Ca²⁺ fluctuations in DS astroglia.

376

377

378

379



381 **Figure 5. S100 β regulates spontaneous Ca²⁺ fluctuations in DS astroglia.** (a–b) Immunostaining of S100 β in iPSC-derived
382 astroglia revealed increased expression in DS astroglia compared with isogenic DS2UA (3 images of immunostaining, 12.5 \pm 1.0%
383 for DS2UA, 80.4 \pm 1.8% for DS1A, 75.3 \pm 2.9% for DS4A, P <0.01). Scale bar: 50 μ m. (c) Representative ROIs (n =20) showing
384 spontaneous Ca²⁺ fluctuations in populations of DS4A with and without S100 β KD. Scale bars: 50 μ m. (d–e) The number of Ca²⁺
385 events was significantly decreased in DS4A populations with decreased expression of S100 β . The normalized S100 β expression
386 levels (3 RNA samples, d) and the number of Ca²⁺ events (3 imaging sessions of 5 min, e) with and without S100 β KD are shown.
387 (f–g) Overexpression of S100 β increased the number of Ca²⁺ events in DS1A. qPCR analysis confirmed elevated expression of
388 S100 β in DS1A when S100 β was overexpressed (3 RNA samples, 4.8 \pm 0.2-fold relative to empty vector group, P <0.01, f). 2-fold
389 more Ca²⁺ events in 5 min were detected in DS1A when S100 β was overexpressed (3 imaging sessions, g). (h) Blocking
390 intracellular Ca²⁺ events by S100 β KD increased activity of H9 hESC-derived neurons co-cultured with DS4A. The fluorescence
391 changes of H9 hESC-derived neurons in response to 40 FPs stimuli co-cultured with 2 populations of DS4A are shown. (i)
392 Hypothetic model. DS astroglia exhibit aberrant Ca²⁺ fluctuations, which are dependent on IP₃R-ER pathway, and can be modulated
393 by ATP and HSA21 gene *S100 β* . The elevated Ca²⁺ fluctuations inhibit neuronal activity, which can be rescued by blocking either
394 aberrant Ca²⁺ fluctuations or adenosine receptors. P <0.01 (**) or 0.05 (*), unpaired t-test. Error bars represent mean \pm s.e.m.

395

396 Given the reported role of secreted S100 β protein in modulating neural activity, we incubated
397 the cultures with antibodies against S100 β or Tuj1 (without permeabilization). After 10 minutes
398 incubation, there was no effect on spontaneous Ca²⁺ events of either antibody (**Supplementary**
399 **Fig. 7b**), suggesting that the spontaneous Ca²⁺ events are mediated by intracellular S100 β .

400

401 We then asked whether overexpression of S100 β protein would also modulate spontaneous
402 Ca²⁺ fluctuations. We overexpressed *S100 β* in DS1A (**Fig. 5f**), in which the number of
403 spontaneous Ca²⁺ transients is less abundant than DS4A. After two days of expression, we
404 observed a 2-fold increase in the number of Ca²⁺ transients (P <0.01; **Fig. 5g**). Thus, we
405 conclude that increased cytosolic S100 β expression is both necessary and sufficient to drive
406 the spontaneous Ca²⁺ fluctuations observed in DS astroglia.

407

408 Finally, we examined whether DS astroglia with spontaneous Ca²⁺ fluctuations alleviated by
409 *S100 β* KD still suppressed neuronal excitability. We recorded evoked Ca²⁺ events in response

410 to FP stimuli in H9 neurons co-cultured with DS4A with or without *S100β* KD. H9 neurons co-
411 cultured with DS4A with potent *S100β* KD displayed significantly larger (1.7-fold; $P=0.0027$)
412 neural activity than those without *S100β* KD (**Fig. 5h**), suggesting that *S100β* KD successfully
413 rescued neuronal activity suppressed by DS4A. Thus, together with the findings above (**Fig. 3d**),
414 we conclude that blocking Ca^{2+} fluctuations in DS astroglia by genetic ablation of either *IP₃R2* or
415 *S100β* is sufficient to rescue the excitability decreases of co-cultured neurons.

416

417 In summary, our data indicate the functional importance of astrocyte-neuron interplay in
418 regulating neuronal excitability in a DS-iPSCs based model. The aberrant Ca^{2+} fluctuations in
419 human DS astrocytes depend on intracellular IP_3 -ER Ca^{2+} release and are mediated by the
420 overexpression of HSA21 protein *S100β*. Blocking spontaneous Ca^{2+} fluctuations in DS
421 astroglia or adenosine-mediated astrocyte-neuron signaling successfully rescued suppressed
422 neuronal excitability (**Fig. 5i**).

423

424

425

426

427 **Discussion**

428 Combining human stem cell technology with genetically encoded Ca^{2+} indicators and
429 quantitative analysis tools provides a powerful platform to study neuron-astrocyte interaction, in
430 both physiological and pathological conditions, especially at early developmental stages. Using
431 this platform, we imaged and characterized the effect of Ts21-iPSC–derived astroglia on
432 neuronal networks. DS astroglia produced structural and functional deficits in co-cultured
433 neurons. Specifically, neurons co-cultured with DS astroglia displayed decreased global
434 excitability. Such decreased global excitability of neurons corresponded with increased
435 amplitudes of post-synaptic activity and synaptic density, consistent with accepted mechanisms
436 of homeostatic synaptic plasticity and synaptic scaling⁴⁶. More importantly, our data is in line
437 with a rodent DS model (overexpression of Ts21 gene, *Dyrk1a*) study, in which the dendritic
438 spine density and mEPSC amplitude increased while frequency of mEPSCs remained
439 unchanged in prefrontal cortical pyramidal neurons.³⁰ It is worth investigating whether this
440 alteration of synaptic properties could also be imposed by astrocytes in the *Dyrk1a* rodent
441 model.

442
443 We further showed functional differences between DS astroglia and control isogenic astroglia in
444 terms of intracellular Ca^{2+} dynamics. We observed elevated spontaneous Ca^{2+} fluctuations that
445 are frequent and periodic only in DS-derived astroglia, but not in an isogenic control cells. These
446 aberrant Ca^{2+} fluctuations in DS astroglia are necessary to drive suppression of global
447 excitability in co-cultured neurons, as evidenced by rescue by genetic or pharmacological block.

448
449 What causes aberrant Ca^{2+} fluctuations in DS astroglia? In the present study, we demonstrate
450 that overexpression of cellular S100 β in DS astroglia mediates elevated spontaneous Ca^{2+}
451 fluctuations, which subsequently regulate neuronal excitability (**Fig. 5g-h**). This finding is of

452 particular interest, as S100 β is a Ca²⁺-binding protein. Previous research⁴⁷ has shown that
453 secreted S100 β stimulates a rise in intracellular Ca²⁺ concentration in both neurons and glia.
454 Furthermore, extracellular S100 β regulates the firing patterns of neurons by reducing
455 extracellular Ca²⁺ concentrations⁴⁴. In our studies, extracellular S100 β did not influence
456 spontaneous Ca²⁺ fluctuations in DS astroglia, whereas cytosolic of S100 β did. Further
457 investigation is necessary to parse the various functions of secreted and cytosolic S100 β in
458 healthy and disease-model astrocytes and neurons.

459
460 A major open question in DS research is the mechanism by which the overdose of hundreds of
461 genes on HSA21 disrupts brain function. To date, several candidate genes have been identified,
462 including *DYRK1A*, *SIM2*, *DSCAM*, *KCNJ6*, *NKCC1*, and *miR-155*^{1,48,49} (**Supplementary table**
463 **1**). Overexpression of S100 β , at the distal end of the HSA21 long arm, has been shown to
464 generate reactive oxygen species (ROS)²⁵ in hiPSC-derived DS astroglia, leading to neuronal
465 apoptosis³. Previous research reported that ROS induce lipid peroxidation, activate the PLC-
466 IP₃R pathway, and cause Ca²⁺ increases in astrocytes⁵⁰. Indeed, we found that spontaneous
467 Ca²⁺ activity was mediated by IP₃R2-regulated ER stores. Though we do not have direct
468 evidence to link S100 β , ROS, and PLC-IP₃R, S100 β might mediate perturbed Ca²⁺ dynamics via
469 ROS in DS astroglia.

470
471 Our study provides additional evidence to support the hypothesis that astrocytic Ca²⁺ signaling
472 modulates neural activity, critical for brain function during development. A grand challenge is to
473 elucidate the pathways regulating astrocyte-neuron interplay during development. In the present
474 study, our results indicate that astrocyte-neuron interaction via purinergic signaling might be a
475 significant contributor linking aberrant astrocytic Ca²⁺ to neuronal functional deficits in DS. We
476 showed that treatment with DPCPX, an adenosine A₁ receptor antagonist, rescued the

477 suppressed Ca^{2+} activity of H9 hESC-derived neurons co-cultured with DS astroglia (**Fig. 1i**). To
478 what extent ATP potentiates and/or inhibits neuronal activity is still under debate; however,
479 adenosine predominantly inhibits synaptic activity via A_1 receptors^{33–35}.

480

481 In conclusion, the combination of a human iPSC DS model with functional imaging, and
482 pharmacological and genetic manipulation provides a platform for quantitative measurement of
483 human cellular physiology and for mechanistic studies of disease pathophysiology. Though
484 animal models of neurological disorders play an important role in studying the effects of specific
485 genetic and experimental perturbations and in testing potential treatments, they often fail to
486 faithfully recapitulate the full spectrum of human phenotypes, which can lead to false
487 conclusions owing to molecular and cellular differences between the systems. Future
488 improvements to iPSC models will include 3-dimensional culture⁵¹, multi-color imaging, and
489 incorporating genetically encoded indicators for other molecules and cellular states (*e.g.*
490 glutamate)⁵². Our imaging platform can be applied to the study of other neurological diseases,
491 as well, even to the level of testing specific drug combinations on neuron-astrocyte co-cultures
492 developed from single healthy or diseased individuals.

493

494

495

496 **Materials and Methods**

497 **Plasmid construction**

498 *IP₃R2*, *S100β*, and scrambled shRNA KD plasmids were ordered from Sigma (MISSION®
499 shRNA Library, pLKO.1 with *U6* promoter driving shRNA expression). Lentiviruses were
500 produced in HEK293T cells and used to infect astrocytes. To construct shRNA-mCherry
501 plasmids, shRNA plasmids were digested with KpnI and BamHI (New England BioLabs; Ipswich,
502 MA). mCherry flanked by KpnI and BamHI was ligated into the shRNA vector. To construct *PGK*
503 promoter-driven *S100β*, *S100β* was amplified by PCR using astrocytic cDNA as a template,
504 digested with KpnI and BamHI, and then ligated to plasmids digested with KpnI and BamHI.

505

506 **Neural differentiation of human ESCs and iPSCs**

507 H9 human ESCs were obtained from WiCell (Madison, WI). Control isogenic trisomy 21 and
508 euploid iPSCs, DS1, DS2U, and DS4, were engineered in Dr. Anita Bhattacharyya's lab, as
509 previously described⁴. H9 ESCs and iPSCs were maintained on matrigel (Becton-Dickinson,
510 356234) in mTeSR1 medium (StemCell Technologies, 05850). Mycoplasma contamination was
511 tested for routinely. We used previously described protocols for neural differentiation²⁹, with
512 minor modifications. Inhibitors of SMAD signaling (10 μ M SB431542 and 100 nM LDN193189,
513 both from Tocris) were added for the first 6 days to promote neural induction²⁸.

514

515 **Derivation and culture of astrocytes**

516 Control isogenic and DS iPSCs were differentiated into neural progenitors and cultured as
517 spheres for 3 months. The astrospheres were attached to fibronectin-coated dishes (Sigma,
518 F0895), dissociated into single cells, and cultured in an optimized commercial medium for
519 human primary astrocytes (ScienCell Research Laboratories, 1801). Human primary astrocytes
520 (HA) were also from ScienCell Research Laboratories (1800). We performed karyotype analysis

521 to confirm the trisomy states of DS1- and DS4-derived astroglia (DS1A and DS4A), and the
522 disomy state of control isogenic line DS2U-derived astroglia (DS2UA), prior to and after the Ca^{2+}
523 experiments using a service provided by Cell Line Genetics. Indeed, chromosome alteration
524 usually occurs more frequently during the maintenance of iPSCs before differentiation⁵³.
525 The cell size was analyzed by randomly selecting 5 cells from 3 bright field images. Pixel areas
526 of each selected cell were calculated and averaged in ImageJ.

527

528 **Lentivirus production**

529 Lentiviruses were produced by co-transfecting HEK293T cells (ATCC) with 5 μg pSIV-*Synapsin-*
530 *1*-GCaMP6m or pHIV-*EF1 α* -Lck-GCaMP6m, scrambled or S100 β shRNAs, 2 μg pHCMV-G, and
531 3 μg pCMV-deltaR8.2, using 40 μl SuperFect (Qiagen, 301305). Supernatant containing viral
532 particles was collected, filtered, and concentrated 72 h later with an Ultra-4 centrifugal filter
533 (Millipore, UFC810024).

534

535 **Ca^{2+} imaging and analysis in astrocytes**

536 Primary astrocytes or iPSC-derived astrocytes were seeded onto 8-well slides (Ibidi, 80826,
537 optically clear), coated with fibronectin and infected with lentiviruses encoding GCaMP6m driven
538 by the *EF1 α* promoter, then subjected to Ca^{2+} imaging. For *IP₃R2* KD, DS4A cells were infected
539 with lentiviruses encoding shRNA and GCaMP6m; Ca^{2+} imaging followed. For *S100 β* KD, DS4A
540 cells were infected with lentiviruses encoding shRNA, sorted into 2 populations by FACS
541 according to mCherry intensity, and infected with GCaMP6m for each population; Ca^{2+} imaging
542 followed. For each cell line, 3 Ca^{2+} -imaging sessions (each session contains 3 fields of view)
543 were collected from independent samples. For mixed cultures of control isogenic and DS
544 astrocytes, control isogenic DS2UA were first infected with lentiviruses expressing *EF1 α -*
545 GCaMP6m, then seeded with DS4A, followed by Ca^{2+} imaging. Three days post-infection, frame

546 scans were acquired at 2 Hz (512x512 pixels) for a period of 300 s using a Zeiss LSM 710
547 confocal microscope ($\times 20$ magnification, N.A.=0.8 objective). Agonists or antagonists (Tocris)
548 were added at frame 10 during continuous imaging. For quantification of ATP and glutamate-
549 evoked activity, to eliminate the confound of spontaneous activity, only ROIs that were silent
550 during the initial imaging period were analyzed for a response to added ATP or glutamate.
551 Furthermore, we ensured that these evoked responses were time-locked to agonist application.

552

553 Because of these complex spatiotemporal patterns of Ca^{2+} dynamics in astrocytes, we
554 developed a computational tool, named FASP⁴⁰, to quantitatively and automatically analyze the
555 large-scale imaging datasets to ensure that the analysis is identical and objective for all cells
556 and across experiments. As an unsupervised analytic method, FASP is data-driven, learning
557 model parameters using machine-learning techniques to automatically detect ROIs displaying
558 Ca^{2+} fluctuation. In addition, designed under probabilistic principles, FASP has strong statistical
559 power to detect weak signals (ROIs) that are easily ignored by purely manual analysis. Our
560 simulation study verified that some ROIs with weak signals were ignored by manual analysis but
561 correctly detected by FASP. By judicious application of various statistical theories, FASP
562 confers tuning parameters with probabilistic meaning, which can be directly translated into the
563 false discovery rates. This algorithm greatly facilitates the usability of parameter settings and
564 ensures the reproducibility of the results and equal comparison across experiments.

565

566 Specifically, we set a single threshold corresponding to a false discovery rate of 0.01; that is, an
567 average of 1% of all identified active ROIs are expected to be false positives. The threshold is
568 fixed for all experiments and conditions.

569

570 Given a time-lapse astrocytic Ca^{2+} -imaging data set, FASP generates a set of ROIs and
571 corresponding characteristic curves. For each pixel in an ROI, there is a corresponding activity

572 curve for which the time shift with respect to the characteristic curve is also estimated. Based on
573 the results of FASP, we quantified various parameters of astrocytic Ca²⁺ signals according to the
574 following:

- 575 • The signal-to-baseline ratio of fluorescence was calculated as

$$576 \quad \frac{\Delta F}{F_0} = \frac{F - F_0}{F_0},$$

577 where the baseline fluorescence F_0 is estimated as the 10th percentile of the
578 fluorescence level over all time points of the measurement.

- 579 • The number of Ca²⁺ transients is calculated as the number of peak responses from all
580 ROIs detected in each time-lapse imaging session.
- 581 • The number of active ROIs is calculated as the total number of ROIs detected by FASP
582 in the field of view of each time-lapse imaging session.

583

584 **Amplitude:** To calculate the amplitude of a Ca²⁺ transient we first transformed the raw time-
585 intensity curves into signal-to-baseline ratio of fluorescence ($\Delta F/F_0 = (F - F_0)/F_0$), where the
586 baseline fluorescence F_0 is estimated as the 10th percentile of the fluorescence levels
587 (intensities) at all the time points during measurement.

588

589 **Frequency:** To calculate the frequency of Ca²⁺ fluctuations more reliably, we first determined
590 the average duration between 2 contiguous events, and then defined the frequency as the
591 inverse of the average duration. For those ROIs that only displayed single Ca²⁺ transients during
592 the imaging session, the information contained in the single-event time series is insufficient for
593 point estimation of frequency. These ROIs are expected to have a positive frequency between 0
594 and 0.2 transients per minute.

595

596 **T_{0.5}**: Decay kinetics or T_{0.5}(off) was calculated using linear interpolation as the time from peak to
597 half-amplitude of an event.

598
599 **Propagation speed wavefront analysis**: On the basis of estimated pixel-wise time shifts from
600 the characteristic curve, wavefronts of Ca²⁺ transients were located; accordingly, the
601 propagation speed of Ca²⁺ events within an ROI was obtained by estimating the average
602 distance between wavefronts. Active ROIs detected in DS4A were divided into 33 clusters of
603 timed coincidence by unsupervised clustering analysis (Affinity Propagation Clustering
604 Algorithm)⁵⁴. Any pairs of ROIs within the same cluster were recognized as highly coincident,
605 while any pairs of ROIs from 2 different clusters were recognized as weakly coincident.
606 Distributions of pixel distance of correlated and uncorrelated pairs were then measured and
607 plotted.

608

609 **Neuron-astrocyte co-culture and imaging**

610 Neurospheres were seeded on matrigel-coated glass-bottom dishes (MatTek, P35G-1.0-14-C),
611 and cultured in neuronal medium [neurobasal medium, 21103-049; 1% N-2 supplement, 17502-
612 048, 2% B-27 supplement, 17504-044; 10 ng/ml BDNF (450-02) and GDNF (450-10)] for 40
613 days. The medium components were purchased from Thermo Fisher Scientific, and cytokines
614 from Peprotech. Neurons were then infected with lentiviruses expressing *Synapsin-1*-
615 GCaMP6m. Two days post-infection, astrocytes were seeded on top of neurons to establish co-
616 culture. After 3–7 days, infected neurons were stimulated using a custom-built field stimulator
617 with platinum wires and imaged using a Zeiss LSM 710 confocal microscope (× 20
618 magnification, 0.8 NA, 512x512 pixels, 458 ms/frame). Field stimuli were delivered as 40 V, 30
619 Hz, 1 ms pulses for the following trains: 10, 20, 40, 80 field stimuli in HBSS with 2mmol CaCl₂
620 and MgCl₂. When chemicals were used, they were applied 3 days prior to imaging, except
621 DPCPX, which was acutely applied 1 h prior to imaging. All chemicals were purchased from

622 Tocris. All neuronal imaging experiments were repeated 3 times, and 10 ROIs were selected for
623 analysis using a customized script (FluoAnalyzer) in MATLAB (MathWorks). ROIs ($n > 10$ for
624 each imaging file) were manually selected, and the fluorescence intensity (F) at each frame was
625 quantified as the mean of all selected ROIs. The neuronal responses were calculated as $\Delta F/F$
626 ($F - F_0/F_0$), where F was quantified as the mean of all selected ROIs ($n > 10$ in each field of view),
627 and F_0 was taken as the mean of all ROIs across the first 3 frames.

628

629 **Immuncytochemistry**

630 Cells maintained on cover glasses (Fisher Scientific, 12-545-81) were washed with PBS 3 times
631 before being fixed with 4% paraformaldehyde (VWR, 100503-916) for 15 min. After washing,
632 cells were treated with 0.1% Triton X-100 (Fisher Scientific, BP151-500) for 10 min, blocked
633 with 10% bovine serum albumin (Sigma, A9647) for 60 min, and incubated with primary
634 antibodies at 4 °C overnight followed by secondary antibodies for 1 h at room temperature. Cells
635 were washed with PBS 2 times after each antibody incubation and mounted on glass slides
636 (Fisher Scientific, 12-550-123) using ProLong® Gold Anti-fade Mountant with DAPI (Thermo
637 Fisher Scientific, P36935). Primary antibodies used included: AQP4 (Santa Cruz Biotech, sc-
638 20812, rabbit), CD44 (Abcam, ab6124, mouse), GFAP (Millipore, MAB360, mouse; AB5840,
639 rabbit), TUJ1 (COVANCE, MMS-435P, mouse), Synapsin-I (Millipore, AB1543, rabbit), S100 β
640 (Abcam, ab11178, mouse), and PSD95 (NeuroMab, K28/43, mouse). Secondary antibodies
641 included Alexa488-conjugated donkey anti-rabbit (A21206) and Alexa594-conjugated goat anti-
642 mouse (A11005), and were purchased from Thermo Fisher Scientific.

643

644 **Immunocytochemistry analysis**

645 Images were obtained using a Zeiss LSM 710 confocal microscope ($\times 40$ magnification, N.A.
646 1.3 oil objective). All immunostaining experiments were performed 3 times, and representative
647 results were presented.

648

649 Puncta density quantification: Using the spot-detection feature in the Imaris software (Bitplane)
650 the number of colocalized Synapsin-1 and PSD95 per μm of dendrite was obtained to calculate
651 the puncta density. S100 β immunocytochemistry analysis: Using FIJI the fluorescence intensity
652 of each imaging field was analyzed.

653

654 **mEPSC recordings**

655 Whole-cell voltage clamp experiments were performed 17–19 days after plating. mEPSCs were
656 recorded in an external solution containing 140 mM NaCl, 5 mM KCl, 10 mM HEPES, 2 mM
657 CaCl₂, 1 mM MgSO₄, 1 μM tetrodotoxin (TTX), 50 μM AP-5, and 20 μM bicuculline (pH 7.4 with
658 NaOH, 290 mOsm/l). Borosilicate glass electrodes were filled with an internal solution
659 containing 145 mM CsCl, 1 mM EGTA, 5 mM HEPES, 0.1 mM CaCl₂, 2 mM MgSO₄ (PH 7.4
660 with CsOH, 275 mOsm/l). The seal resistance was greater than 1 G Ω and the series resistance
661 was no greater than 20 M Ω . All recordings were made with an Axopatch 200B patch-clamp
662 amplifier (Axon Instruments, Foster City, CA, USA). Whole-cell currents were filtered at 2 kHz
663 and digitized at 10 kHz. All neurons were voltage-clamped at -60 mV.

664

665 **mEPSC analysis**

666 The mEPSC events were detected with Mini Analysis software (Synaptosoft Inc., Fort Lee, NJ,
667 USA). The accuracy of detection was confirmed by visual inspection.

668

669 **RNA isolation and qPCR**

670 Total RNA was prepared from cells ($n=3$) with RNeasy kit (Qiagen, 74104). Complementary
671 DNA was prepared with iScript RT Supermix (Bio-Rad, 170-8841). qPCR was performed with

672 iTaq™ Universal SYBR® Green Supermix (Bio-Rad, 172-5121) on a CFX96™ Real-Time
673 System (Bio-Rad), and the data was collected with Bio-Rad CFX Manager 3.0. Gene expression
674 levels were quantified relative to the housekeeping gene, *GAPDH*.

675

676 **Single-cell expression analysis**

677 DS astrocytes were digested and then sorted by FACS to get rid of cell debris and dead cells.

678 The cell suspension was loaded onto a C1 Single-Cell Auto Prep Array for mRNA Seq (10–17
679 μm ; Fluidigm, 100-5760), and single cells were captured and lysed to get cDNA on Fluidigm's

680 C1 platform. Gene expression patterns of single cells ($n=46$) were studied using the 48.48

681 Dynamic Array Chip for Gene Expression (Fluidigm, BMK-M48.48), which assembles cDNA

682 from individual cells to create individual qPCR reactions following the manufacturer's

683 instructions.

684

685 The values of gene expression were pre-processed by taking the inverse, applying a square-

686 root transformation, and rescaling the expression to zero mean and unit variance. The similarity

687 matrix was computed first using the default method of negative distance (default parameters),

688 and affinity propagation clustering was applied by setting the desired number of clusters to 2 in

689 the R package, Apcluster.

690

691 The single-cell expression analysis consisted of 4 major components. First, pre-processing was

692 conducted to impute missing values and make sure the expression values were approximated

693 well by Gaussian distributions to facilitate follow-up analysis. Second, clustering analysis was

694 done to discover groups within the cell populations. Third, significance tests were implemented

695 to determine whether the resultant clusters were purely due to chance. Fourth, differential

696 analysis was used to find the genes underpinning the clusters. Detailed discussion about these

697 4 components follows.

698

699 **Preprocessing:** In the raw data, the value for each gene denotes how many amplification
700 cycles were required to cross the threshold, which is set using the AutoGlobal method. In our
701 data, the maximum observed value was 29. A missing value indicated that the corresponding
702 gene had too little expression to be amplified to reach the threshold quantity. In the raw data,
703 missing values were marked by 999. We replaced all missing values by 60, which was around 2
704 times the maximum value observed. Then, the inverse of the values was used to represent the
705 amount of expression. A square-root transformation was applied to each gene to normalize for
706 expression-level differences. Finally, for each cell, all genes were normalized to have zero mean
707 and unit variance to highlight differences between cells.

708

709 **Clustering analysis:** Affinity propagation clustering (APC) was applied. The algorithm was
710 implemented in the R package, Apcluster. The algorithm requires users to input a similarity
711 matrix. The default settings were adopted; in other words, Euclidian distance was calculated
712 based on the data matrix and the negative distance was used as the similarity matrix. To be
713 consistent with the observation that there were 2 groups of astrocytes, one with active Ca^{2+}
714 fluctuations and the other one without, the desired number of clusters was set to 2. Notably, we
715 did not know which cells were active, and the analysis was unsupervised.

716

717 **Assessing statistical significance of resultant clusters:** Since a clustering algorithm can
718 always generate clusters even if there are no clusters actually present in the data, we sought to
719 evaluate whether the resultant clusters were purely by chance. The null hypothesis was that
720 there were no groups of cells that were closer within-group than between-groups (i.e., distances

721 between cells were uniformly distributed). Permutation was used to generate the distribution for
722 the null hypothesis. All genes in the data set were permuted 100,000 times, resulting in 100,000
723 data sets following the null hypothesis. For each resulting data set, we ran APC to get 2 groups.
724 In APC, the objective function was the overall similarity. A histogram was obtained based on the
725 100,000 overall similarities. The position of the observed overall similarity indicated the
726 significance of the observed value.

727

728 **Differentially expressed genes between clusters:** Standard differential analysis, such as t-
729 test between groups, cannot be applied here because the clustering was based on all genes;
730 hence, each gene was biased toward differential expression between clusters. To correct for
731 this bias, a permutation procedure was designed. To test the significance for each gene, we
732 shuffled the values in that gene 10,000 times while keeping all other genes fixed. In this way,
733 the gene would not interfere with the clustering results, so there would be no bias. Each time we
734 ran the clustering algorithm APC to get 2 groups. Based on the new clustering results, the
735 significance of the gene was recorded and summarized into a histogram, which could be further
736 used to derive the corrected *P* value. For example, if the original *P* value was 0.01,
737 corresponding to the 2nd percentile in the histogram, the corrected *P* value would be 0.02.

738

739 **Fluorescence-activated cell sorting (FACS)**

740 DS astrocytes were infected with lentiviruses expressing S100 β -shRNA-mCherry and collected
741 3 days later for sorting, which was performed by the FACS core at UC Davis. The top 15% of
742 cells expressing high amounts of mCherry measured on fluorescence intensity were collected
743 as mCherry “high”, and the bottom 18% of cells expressing low amounts of mCherry were
744 collected as “low”. High mCherry fluorescence represents high expression of S100 β shRNA and
745 less expression of S100 β .

746

747 **Inhibiting extracellular S100 β**

748 S100 β (Abcam, ab11178, mouse) and TUJ1 (COVANCE, MMS-435P, mouse) antibodies
749 (diluted 1:1000) were used to pretreat DS astrocytes. Following a 10 minute incubation cells
750 infected with pHIV-*EF1 α* -Lck-GCaMP6m were subjected to Ca²⁺ imaging.

751

752 **Karyotype analysis**

753 Karyotype analysis was performed by Cell Line Genetics (Madison, WI).

754

755 **Statistical analysis**

756 All values are shown as mean \pm s.e.m. To determine significant differences between groups,
757 comparisons were made using a two-tailed unpaired t-test. For the modulation of Ca²⁺
758 fluctuation by ATP, two-tailed paired t-test was used. For mEPSC analysis, a one-way ANOVA
759 was used to compare mEPSC amplitude and frequency among groups, followed by Fisher's
760 LSD pairwise comparison when appropriate. For single-cell expression analysis, a permutation
761 test was applied for unsupervised clustering, and the differences of each gene between the two
762 clusters were determined using two-sample unpaired Wilcoxon rank-sum test. A *P* value smaller
763 than 0.05 was accepted for statistical significance. The sample size for each experiment was
764 determined either by power analysis (2-Sample, 2-Sided Equality) or by referring to the sample
765 size in similar studies^{3,42}. For Ca²⁺ imaging experiments, imaging sessions were collected from
766 at least 3 batches of cells, and ROIs were selected either automatically by FASP for astrocyte
767 Ca²⁺ imaging or manually for neuronal Ca²⁺ imaging. For gene expression, RNA samples from
768 three batches of cells were used. For immunostaining analysis, three batches of cells were fixed
769 and five fields of view from each sample were selected for imaging. No randomization or
770 blinding was used. No data was excluded.

771 **Acknowledgments**

772 This work was supported by the Hartwell foundation (L.T.), NIH DP2 MH107059 (L.T.), and NIH
773 R03 HD064880 (A.B.). This project was supported by the University of California, Davis, Flow
774 Cytometry Shared Resource Laboratory; and with technical assistance from Ms. Bridget
775 McLaughlin and Mr. Jonathan Van Dyke. We would like to give special thanks to Dr. Bart
776 Borghuis for generously sharing the FluoAnalyzer codes, Dr. Karen Zito, Dr. Tommaso
777 Patriarchi and Brian McGrew for their critical input and Lisa Makhoul for editorial assistance.

778

779 **Author Information**

780 The authors declare no conflicts of interest.

781

782

783 **References**

- 784 1. Dierssen, M. Down syndrome: the brain in trisomic mode. *Nat. Rev. Neurosci.* **13**, 844–858
785 (2012).
- 786 2. Das, I. & Reeves, R. H. The use of mouse models to understand and improve cognitive
787 deficits in Down syndrome. *Dis. Model. Mech.* **4**, 596–606 (2011).
- 788 3. Chen, C. *et al.* Role of astroglia in Down’s syndrome revealed by patient-derived human-
789 induced pluripotent stem cells. *Nat. Commun.* **5**, 4430 (2014).
- 790 4. Weick, J. P. *et al.* Deficits in human trisomy 21 iPSCs and neurons. *Proc. Natl. Acad. Sci. U. S.*
791 *A.* **110**, 9962–9967 (2013).
- 792 5. Cao, X. *et al.* Astrocyte-derived ATP modulates depressive-like behaviors. *Nat. Med.* **19**,
793 773–777 (2013).
- 794 6. Di Giorgio, F. P., Boulting, G. L., Bobrowicz, S. & Eggan, K. C. Human embryonic stem cell-
795 derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing
796 mutation. *Cell Stem Cell* **3**, 637–648 (2008).
- 797 7. Marchetto, M. C. N. *et al.* Non-cell-autonomous effect of human SOD1 G37R astrocytes on
798 motor neurons derived from human embryonic stem cells. *Cell Stem Cell* **3**, 649–657 (2008).
- 799 8. Tong, X. *et al.* Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in
800 Huntington’s disease model mice. *Nat. Neurosci.* **17**, 694–703 (2014).
- 801 9. Molofsky, A. V. *et al.* Astrocytes and disease: a neurodevelopmental perspective. *Genes Dev.*
802 **26**, 891–907 (2012).

- 803 10. Bambrick, L. L., Yarowsky, P. J. & Krueger, B. K. Altered astrocyte calcium homeostasis and
804 proliferation in the Ts65Dn mouse, a model of Down syndrome. *J. Neurosci. Res.* **73**, 89–94
805 (2003).
- 806 11. Ballestín, R. *et al.* Astrocytes of the murine model for Down Syndrome Ts65Dn display
807 reduced intracellular ionic zinc. *Neurochem. Int.* **75**, 48–53 (2014).
- 808 12. Torres, M. D., Garcia, O., Tang, C. & Busciglio, J. Dendritic spine pathology and
809 thrombospondin-1 deficits in Down syndrome. *Free Radic. Biol. Med.* (2017).
810 doi:10.1016/j.freeradbiomed.2017.09.025
- 811 13. Garcia, O., Torres, M., Helguera, P., Coskun, P. & Busciglio, J. A role for thrombospondin-1
812 deficits in astrocyte-mediated spine and synaptic pathology in Down's syndrome. *PLoS One*
813 **5**, e14200 (2010).
- 814 14. Khakh, B. S. & McCarthy, K. D. Astrocyte calcium signaling: from observations to functions
815 and the challenges therein. *Cold Spring Harb. Perspect. Biol.* **7**, a020404 (2015).
- 816 15. Wang, X. *et al.* Astrocytic Ca²⁺ signaling evoked by sensory stimulation in vivo. *Nat.*
817 *Neurosci.* **9**, 816–823 (2006).
- 818 16. Angulo, M. C., Kozlov, A. S., Charpak, S. & Audinat, E. Glutamate released from glial cells
819 synchronizes neuronal activity in the hippocampus. *J. Neurosci. Off. J. Soc. Neurosci.* **24**,
820 6920–6927 (2004).
- 821 17. Lee, S. *et al.* Channel-Mediated Tonic GABA Release from Glia. *Science* **330**, 790–796 (2010).
- 822 18. Mothet, J.-P. *et al.* Glutamate receptor activation triggers a calcium-dependent and SNARE
823 protein-dependent release of the gliotransmitter D-serine. *Proc. Natl. Acad. Sci. U. S. A.* **102**,
824 5606–5611 (2005).

- 825 19. Newman, E. A. Propagation of intercellular calcium waves in retinal astrocytes and Müller
826 cells. *J. Neurosci. Off. J. Soc. Neurosci.* **21**, 2215–2223 (2001).
- 827 20. Wolosker, H., Balu, D. T. & Coyle, J. T. The Rise and Fall of the d-Serine-Mediated
828 Gliotransmission Hypothesis. *Trends Neurosci.* **39**, 712–721 (2016).
- 829 21. Sloan, S. A. & Barres, B. A. Looks can be deceiving: reconsidering the evidence for
830 gliotransmission. *Neuron* **84**, 1112–1115 (2014).
- 831 22. Ota, Y., Zanetti, A. T. & Hallock, R. M. The role of astrocytes in the regulation of synaptic
832 plasticity and memory formation. *Neural Plast.* **2013**, 185463 (2013).
- 833 23. Busciglio, J. *et al.* Altered Metabolism of the Amyloid β Precursor Protein Is Associated with
834 Mitochondrial Dysfunction in Down's Syndrome. *Neuron* **33**, 677–688 (2002).
- 835 24. Krencik, R., Weick, J. P., Liu, Y., Zhang, Z.-J. & Zhang, S.-C. Specification of transplantable
836 astroglial subtypes from human pluripotent stem cells. *Nat. Biotechnol.* **29**, 528–534 (2011).
- 837 25. Esposito, G. *et al.* Genomic and functional profiling of human Down syndrome neural
838 progenitors implicates S100B and aquaporin 4 in cell injury. *Hum. Mol. Genet.* **17**, 440–457
839 (2008).
- 840 26. Wolvetang, E. J. *et al.* ETS2 overexpression in transgenic models and in Down syndrome
841 predisposes to apoptosis via the p53 pathway. *Hum. Mol. Genet.* **12**, 247–255 (2003).
- 842 27. Busciglio, J. & Yankner, B. A. Apoptosis and increased generation of reactive oxygen species
843 in Down's syndrome neurons in vitro. *Nat. Lond.* **378**, 776–9 (1995).
- 844 28. Chambers, S. M. *et al.* Highly efficient neural conversion of human ES and iPS cells by dual
845 inhibition of SMAD signaling. *Nat. Biotechnol.* **27**, 275–280 (2009).

- 846 29. Zhang, S. C., Wernig, M., Duncan, I. D., Brüstle, O. & Thomson, J. A. In vitro differentiation of
847 transplantable neural precursors from human embryonic stem cells. *Nat. Biotechnol.* **19**,
848 1129–1133 (2001).
- 849 30. Thomazeau, A. *et al.* Prefrontal Deficits in a Murine Model Overexpressing the Down
850 Syndrome Candidate Gene Dyrk1a. *J. Neurosci.* **34**, 1138–1147 (2014).
- 851 31. Busciglio, J., Capone, G., O’Byran, J., O’Byran, J. P. & Gardiner, K. J. Down syndrome: genes,
852 model systems, and progress towards pharmacotherapies and clinical trials for cognitive
853 deficits. *Cytogenet. Genome Res.* **141**, 260–271 (2013).
- 854 32. Adair, T. H. Growth regulation of the vascular system: an emerging role for adenosine. *Am. J.*
855 *Physiol. Regul. Integr. Comp. Physiol.* **289**, R283–R296 (2005).
- 856 33. Koizumi, S. Synchronization of Ca²⁺ oscillations: involvement of ATP release in astrocytes.
857 *FEBS J.* **277**, 286–292 (2010).
- 858 34. Nam, H. W. *et al.* Adenosine and glutamate signaling in neuron-glia interactions:
859 implications in alcoholism and sleep disorders. *Alcohol. Clin. Exp. Res.* **36**, 1117–1125 (2012).
- 860 35. Delekate, A. *et al.* Metabotropic P2Y₁ receptor signalling mediates astrocytic hyperactivity
861 in vivo in an Alzheimer’s disease mouse model. *Nat. Commun.* **5**, 5422 (2014).
- 862 36. Kawamura, M. & Kawamura, M. Long-term facilitation of spontaneous calcium oscillations
863 in astrocytes with endogenous adenosine in hippocampal slice cultures. *Cell Calcium* **49**,
864 249–258 (2011).
- 865 37. Bazargani, N. & Attwell, D. Astrocyte calcium signaling: the third wave. *Nat. Neurosci.* **19**,
866 182–189 (2016).

- 867 38. Anderson, M. A. *et al.* Astrocyte scar formation aids central nervous system axon
868 regeneration. *Nature* **532**, 195–200 (2016).
- 869 39. Chen, T.-W. *et al.* Ultra-sensitive fluorescent proteins for imaging neuronal activity. *Nature*
870 **499**, 295–300 (2013).
- 871 40. Wang, Y. *et al.* A Machine Learning Approach to Functional Astrocyte Phenotyping from
872 Time-Lapse Calcium Imaging Data. in (2016).
- 873 41. Tong, X., Shigetomi, E., Looger, L. L. & Khakh, B. S. Genetically encoded calcium indicators
874 and astrocyte calcium microdomains. *Neurosci. Rev. J. Bringing Neurobiol. Neurol.*
875 *Psychiatry* **19**, 274–291 (2013).
- 876 42. Zhang, Y. *et al.* Purification and Characterization of Progenitor and Mature Human
877 Astrocytes Reveals Transcriptional and Functional Differences with Mouse. *Neuron* **89**, 37–
878 53 (2016).
- 879 43. Shigetomi, E., Tong, X., Kwan, K. Y., Corey, D. P. & Khakh, B. S. TRPA1 channels regulate
880 astrocyte resting calcium and inhibitory synapse efficacy through GAT-3. *Nat. Neurosci.* **15**,
881 70–80 (2011).
- 882 44. Morquette, P. *et al.* An astrocyte-dependent mechanism for neuronal rhythmogenesis. *Nat.*
883 *Neurosci.* **18**, 844–854 (2015).
- 884 45. Nishiyama, H., Knopfel, T., Endo, S. & Itoharu, S. Glial protein S100B modulates long-term
885 neuronal synaptic plasticity. *Proc. Natl. Acad. Sci. U. S. A.* **99**, 4037–4042 (2002).
- 886 46. Turrigiano, G. Homeostatic synaptic plasticity: local and global mechanisms for stabilizing
887 neuronal function. *Cold Spring Harb. Perspect. Biol.* **4**, a005736 (2012).

- 888 47. Barger, S. W., Wolchok, S. R. & Van Eldik, L. J. Disulfide-linked S100 beta dimers and signal
889 transduction. *Biochim. Biophys. Acta* **1160**, 105–112 (1992).
- 890 48. Deidda, G. *et al.* Reversing excitatory GABAAR signaling restores synaptic plasticity and
891 memory in a mouse model of Down syndrome. *Nat. Med.* **21**, 318–326 (2015).
- 892 49. Wang, X. *et al.* Loss of sorting nexin 27 contributes to excitatory synaptic dysfunction by
893 modulating glutamate receptor recycling in Down’s syndrome. *Nat. Med.* **19**, 473–480
894 (2013).
- 895 50. Vaarmann, A., Gandhi, S. & Abramov, A. Y. Dopamine induces Ca²⁺ signaling in astrocytes
896 through reactive oxygen species generated by monoamine oxidase. *J. Biol. Chem.* **285**,
897 25018–25023 (2010).
- 898 51. Paşca, A. M. *et al.* Functional cortical neurons and astrocytes from human pluripotent stem
899 cells in 3D culture. *Nat. Methods* **12**, 671–678 (2015).
- 900 52. Marvin, J. S. *et al.* An optimized fluorescent probe for visualizing glutamate
901 neurotransmission. *Nat. Methods* **10**, 162–170 (2013).
- 902 53. Lund, R. J., Närvä, E. & Lahesmaa, R. Genetic and epigenetic stability of human pluripotent
903 stem cells. *Nat. Rev. Genet.* **13**, 732–744 (2012).
- 904 54. Frey, B. J. & Dueck, D. Clustering by passing messages between data points. *Science* **315**,
905 972–976 (2007).
- 906